Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086606 | 1.00 | ADRB2 (0.52) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| SCHEMBL31247543 | 1.00 | ADRB2 (0.52) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| SCHEMBL594241 | 1.00 | ADRB2 (0.52) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| SCHEMBL14211414 | 1.00 | ADRB2 (0.52) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL14121259 | 0.98 | ADRB2 (0.50) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL14121000 | 0.98 | ADRB2 (0.50) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL14157129 | 0.98 | ADRB2 (0.50) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| SCHEMBL9046864 | 0.83 | SMN1; SMN2 (0.40) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 | |
| SCHEMBL1090665 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2PIK3CDCYP3A4CYP2D6SLC6A2 | |
| SCHEMBL3828644 | 0.82 | PIK3CD (0.43) | ADRB2SMN1; SMN2PIK3CDCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729447-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2014-05-14 | — | — | EP | claimed |
| US-20140044806-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2014-02-13 | — | — | US | claimed |
| WO-2013007621-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2013-01-17 | — | — | WO | claimed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | claimed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| WO-2020114947-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| EP-3372582-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2018-09-12 | — | — | EP | disclosed |
| US-20180250277-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2018-09-06 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250277-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | CHRNG, CHRNA7, CHRNA2 | ADRB2 69/4885SMN1; SMN2 1671/4885PIK3CD 1182/4885 |
| US-20140044806-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | CHRNG, CHRNA7, CHRNA1 | ADRB2 77/4885SMN1; SMN2 1578/4885PIK3CD 1005/4885 |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | ADRB2 77/4885SMN1; SMN2 1578/4885PIK3CD 1005/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | ADRB2 95/4885SMN1; SMN2 642/4885PIK3CD 4406/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | ADRB2 354/4885SMN1; SMN2 4185/4885PIK3CD 763/4885 |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | CDK5, CDK5R1, PPARG | ADRB2 1501/4885SMN1; SMN2 4032/4885PIK3CD 759/4885 |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | ADRB2 646/4885SMN1; SMN2 3647/4885PIK3CD 2278/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | ADRB2 439/4885SMN1; SMN2 3872/4885PIK3CD 726/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | ADRB2 439/4885SMN1; SMN2 3872/4885PIK3CD 726/4885 |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | ADRB2 147/4885SMN1; SMN2 2585/4885PIK3CD 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.